GlassScriptPhysician profile
Khoi Dao
NPI 1518071208
$8,241.36
in general payments reported to CMS, 2019-2025
49 companies · $3,579 in 2025
The $3,579 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $32.85 · 2021: $50.09 · 2022: $486 · 2023: $1,517 · 2024: $2,576 · 2025: $3,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,593 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,593.34 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $2,205.29 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals LP | $622.34 | 2021-2025 | Imfinzi, Calquence, Enhertu |
| Novartis Pharmaceuticals Corporation | $498.58 | 2022-2025 | |
| Pfizer INC. | $324.14 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $307.93 | 2020-2025 | Keytruda, Welireg, Keytruda Qlex |
| Genentech USA, INC. | $265.72 | 2022-2025 | Alecensa, Tecentriq, Venclexta |
| Sobi, INC | $257.09 | 2024-2025 | |
| Exelixis INC. | $237.30 | 2021-2025 | Cabometyx |
| Celgene Corporation | $237.25 | 2022-2025 | Reblozyl, Pomalyst |
| Amgen INC. | $236.88 | 2022-2023 | Nplate, Vectibix, Lumakras |
| Incyte Corporation | $176.55 | 2024-2025 | Jakafi |
| Regeneron Healthcare Solutions, INC. | $171.07 | 2022-2025 | Libtayo |
| Tempus Ai, INC | $168.61 | 2024-2025 | Xt Cdx |
| Beigene USA, INC. | $160.38 | 2023-2024 | Brukinsa |
| Janssen Biotech, INC. | $159.40 | 2022-2025 | Darzalex, Talvey, Tecvayli |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $141.38 | 2023-2025 | Vyloy, Padcev, Xospata |
| Karyopharm Therapeutics INC. | $132.33 | 2023-2025 | Xpovio |
| Genmab U.S., INC. | $128.49 | 2023-2025 | Epkinly, Tivdak |
| Abbvie INC. | $125.71 | 2023-2025 | Venclexta, Lupron Depot |
| Beone Medicines USA, INC. | $118.37 | 2025 | Brukinsa, Tevimbra |
| Glaxosmithkline, LLC. | $115.60 | 2023-2025 | Zejula, Ojjaara, Jemperli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.90 | 2023-2025 | Gilotrif |
| Stemline Therapeutics INC. | $111.01 | 2023-2025 | Orserdu |
| Mirati Therapeutics, INC. | $106.62 | 2023-2024 | Krazati |
| Sumitomo Pharma America, INC. | $100.84 | 2023-2025 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $96.77 | 2024-2025 | Fruzaqla, Alunbrig |
| Emd Serono, INC. | $96.07 | 2024-2025 | |
| Genzyme Corporation | $87.08 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $81.04 | 2020-2024 | Opdivo, Eliquis |
| Sanofi-Aventis U.S. LLC | $69.99 | 2022 | |
| Seagen INC. | $58.50 | 2023 | Padcev, Adcetris |
| Jazz Pharmaceuticals INC. | $52.02 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.36 | 2025 | |
| Array Biopharma INC | $49.46 | 2025 | Braftovi, Mektovi, Lorbrena |
| Lilly USA, LLC | $42.13 | 2025 | Verzenio, Jaypirca |
| Geron Corporation | $39.10 | 2024-2025 | Rytelo |
| Telix Pharmaceuticals | $35.74 | 2025 | Illuccix |
| Azurity Pharmaceuticals, INC. | $25.45 | 2025 | Danziten |
| Ipsen Biopharmaceuticals, INC | $24.95 | 2025 | Onivyde |
| Gilead Sciences, INC. | $24.70 | 2021-2023 | Trodelvy |
| Avyxa Pharma, LLC | $24.45 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $23.45 | 2023 | Imbruvica |
| Puma Biotechnology, INC. | $21.58 | 2024 | |
| Coherus Oncology, INC. | $21.33 | 2025 | Loqtorzi |
| Dendreon Pharmaceuticals LLC | $20.87 | 2024 | Provenge |
| Novocure INC. | $18.40 | 2024 | Optune Lua (Novottf-200t) |
| Inogen, INC. | $18.29 | 2025 | |
| Eisai INC. | $17.81 | 2023 | |
| Octapharma USA, INC. | $17.04 | 2023 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khoi Dao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.